HMGB1 and melanoma: Thus, both Flt3L-induced recruitment of immune cells to the brain and TK-dependent release of the TLR2 agonist HMGB1 are necessary for tumor elimination; together, they are sufficient to induce the regression of a large intracranial glioma and melanoma tumors.